Olivo Alicia C 4

What Happened

• Alicia C. Olivo, EVP, General Counsel & Head of Business Development at Neogenomics (NEO), had 3,944 derivative shares reported as exercised/converted on May 11, 2026 (transaction code M). The filing also shows 2,559 shares disposed to satisfy tax withholding (transaction code F), leaving a net 1,385 shares delivered to her. All entries report $0.00 per share (these were conversions/settlements, not cash purchases or market sales).
• The filing lists both an acquisition entry (3,944 shares acquired on conversion) and disposition entries for tax withholding (2,559) and a derivative disposition (3,944). The practical effect reported is issuance/settlement of shares with a portion withheld for taxes.

Key Details

• Transaction date: May 11, 2026; Form 4 filed May 13, 2026 (appears filed within the standard reporting window).
• Prices reported: $0.00 — reflects conversion/settlement rather than an open-market purchase/sale.
• Gross shares converted: 3,944; shares withheld for taxes: 2,559; net shares delivered: 1,385.
• Transaction codes: M = exercise/conversion of derivative; F = payment of exercise price or tax liability (share withholding).
• Shares owned after transaction: not specified in the Form 4 summary provided.
• Relevant footnotes: the filing references multiple equity grants over prior years (including grants dated May 11, 2023 and grants in 2024–2026). Some awards vest ratably and some are performance-based; the conversion likely relates to previously granted awards that vested or were settled.

Context

• This was a conversion/settlement event (derivative exercise/vesting) with shares withheld to cover tax obligations — a routine administrative occurrence rather than an open-market purchase or sale that signals a trading view.
• For retail investors: purchases are generally more informative as a bullish signal. Here, the net result is Ms. Olivo received 1,385 shares after withholding; no cash proceeds or open-market sale proceeds were reported.